Alvotech higher on positive data backing biosimilar to Takeda's Entyvio
Source: SeekingAlpha
2026-02-05 08:15:45 ET
More on Alvotech, Takeda Pharmaceutical
- Takeda Tests New Highs, But Struggles To Find Entyvio Successor
- Takeda Pharmaceutical Company Limited (TAK) Q3 FY2025 Earnings Call Transcript
- Alvotech: Why FDA Delays Don't Break The Bull Case
- Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar
- Takeda Pharmaceutical Non-GAAP EPS of ¥428.00, revenue of ¥3411.2B; updates FY26 outlook
Read the full article on Seeking Alpha
For further details see:
Alvotech higher on positive data backing biosimilar to Takeda’s Entyvio
Takeda Pharmaceutical Company Limited American Depositary Shares
NASDAQ: TAK
TAK Trading
-0.63% G/L:
$18.115 Last:
1,281,262 Volume:
$18.15 Open:
TAK Latest News
March 02, 2026 02:00:00 am
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
February 24, 2026 09:35:00 am
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
TAK Stock Data
$57,107,745,653
3,115,826,299
N/A
157
N/A
Pharmaceuticals
Healthcare
JP
Chuo-ku
